Provided by Tiger Trade Technology Pte. Ltd.

Viridian Therapeutics, Inc.

28.35
+1.164.27%
Pre-market: 28.12-0.2300-0.81%09:07 EDT
Volume:1.15M
Turnover:32.62M
Market Cap:2.90B
PE:-8.53
High:28.59
Open:27.24
Low:27.10
Close:27.19
52wk High:34.29
52wk Low:9.90
Shares:102.21M
Float Shares:102.00M
Volume Ratio:0.57
T/O Rate:1.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3245
EPS(LYR):-3.3245
ROE:-49.16%
ROA:-27.67%
PB:4.91
PE(LYR):-8.53

Loading ...

Viridian Therapeutics Grants Stock Options to New Employees

Reuters
·
Nov 07, 2025

Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Nov 07, 2025

Viridian Therapeutics Up Over 14%, on Track for Highest Close Since May 2023 -- Data Talk

Dow Jones
·
Nov 07, 2025

H.C. Wainwright Keeps Their Buy Rating on Viridian Therapeutics (VRDN)

TIPRANKS
·
Nov 06, 2025

Viridian Therapeutics Secures $889 Million Financing and Submits BLA for Veligrotug

Reuters
·
Nov 05, 2025

BRIEF-Viridian Therapeutics Q3 Net Income USD -34.599 Million

Reuters
·
Nov 05, 2025

Viridian Therapeutics Q3 Revenue USD 70 Million VS. Ibes Estimate USD 40.3 Thousand

THOMSON REUTERS
·
Nov 05, 2025

Viridian Therapeutics Inc - Cash Position About $887.9 Mln as of Oct 31, 2025

THOMSON REUTERS
·
Nov 05, 2025

Press Release: Viridian Therapeutics Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Dow Jones
·
Nov 05, 2025

Viridian Therapeutics submits BLA to the FDA for veligrotug

TIPRANKS
·
Nov 03, 2025

Viridian Therapeutics Submits BLA to FDA for Veligrotug in Thyroid Eye Disease

Reuters
·
Nov 03, 2025

Viridian Therapeutics Announces Successful October Submission of Biologics License Application (Bla) to U.S. FDA for Veligrotug in Thyroid Eye Disease

THOMSON REUTERS
·
Nov 03, 2025

13D Filings -- Barrons.com

Dow Jones
·
Nov 01, 2025

What Viridian Therapeutics (VRDN)'s Major Financing and Revenue-Sharing Deal Means for Shareholders

Simply Wall St.
·
Oct 29, 2025

Fairmount Funds Management LLC Reports Acquisition of Viridian Therapeutics Common Shares

Reuters
·
Oct 28, 2025

Viridian Therapeutics Advances VRDN-003 Study for Thyroid Eye Disease

TIPRANKS
·
Oct 28, 2025

Analysts Offer Insights on Healthcare Companies: Celcuity (CELC) and Viridian Therapeutics (VRDN)

TIPRANKS
·
Oct 22, 2025

Viridian Therapeutics Announces Pricing Of $251 Million Public Offering Of Shares Of Common Stock

Reuters
·
Oct 22, 2025

Viridian Therapeutics Inc: Selling a Total of 11.4 Mln Shares of Common Stock at a Price of $22 per Share

THOMSON REUTERS
·
Oct 22, 2025

BUZZ-Viridian Therapeutics dips on planned stock deals

Reuters
·
Oct 22, 2025